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The concurrence of ankylosing spondylitis (AS) in a patient
with mixed connective tissue disease (MCTD) is rarely
described in the literature. Significant and sustained efficacy
with tumor necrosis factor (TNF)- blockers has been α
demonstrated in AS patients. However, evidence to date has
revealed associated side effects, including antinuclear antibody
induction and development of a lupus-like syndrome. Several
authors have reported lupus-like manifestations in MCTD
patients treated with TNF- blockers used to control peripheral α
polyarthritis. In our case report, we demonstrate a good
response to etanercept therapy for refractory sacroiliitis in a
patient with coexisting AS and MCTD, without development
of a lupus-like syndrome. This demonstrates that etanercept
therapy may be an appropriate therapeutic agent for sacroiliitis
in MCTD patients, as it is in AS alone.
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INTRODUCTION
Mixed connective tissue disease (MCTD) was
first described as a distinct disease entity charac-
terized by high titers of anti-U1-ribonecleic
protein (RNP) antibodies.
1 With certain sets of
diagnostic criteria, clinical manifestations of MCTD
are similar, or intermingled, with those of other
connective tissue diseases, including systemic
lupus erythematosus (SLE), polymyositis, and
systemic sclerosis.
2 However, a concurrence of
ankylosing spondylitis (AS) and MCTD has rarely
been reported, in spite of their being clinically
distinct entities.
3,4
Most MCTD patients with arthritis respond well
to treatment with nonsteroidal anti-inflammatory
drugs (NSAIDs), hydroxychloroquine, and/or an
oral, low-dose steroid. TNF- blockers, including α
etanercept or infliximab, are also effective in
controlling polyarthritis in MCTD patients,
5,6
although side effects of lupus-like manifestations
have been described. Treatment with TNF-α
blockers in AS has also shown significant clinical
efficacy.
7,8 We present a patient with AS sacro-
iliitis and MCTD who showed good response to
etanercept without development of a lupus-like
syndrome.
CASE REPORT
A 45-year-old female presented with Raynaud’s
phenomenon, photosensitivity, edematous fingers
and hands, and polyarthritis in April 2004. She
also complained of a three-year history of low
back pain with morning stiffness that improved
with exercise and worsened with resting.
Physical examination revealed symmetrical
edematous fingers and hands bilaterally, with
pain and limited motion of the right shoulder.
Chest wall expansion was estimated at 3 cm, and
lumbar spine motion was approximately 2 cm.
Sacroiliac joint tenderness on palpation was noted.
Immunological analyses revealed positive anti-
nuclear antibody (ANA) with specked pattern
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(titer of 1 : 1280, normal < 1 : 40), and positive
anti-RNP antibody (titer of 965, normal < 150).
Antibodies for double-stranded DNA, Sm, SS-A/
Ro, SS-B/La, centromere, Scl-70, and Jo-1 were
negative. Anti-neutrophil cytoplasmic antibody,
anti-cardiolipin antibody, cryoglobulin, VDRL,
and rheumatoid factor were not detected. HLA-
B27 antigen was positive.
On radiographic examination of the pelvis, grade
2 bilateral sacroiliitis was diagnosed according to
the modified New York classification. However,
typical cervical and lumbar spine syndesmophytes
were not identified. Magnetic resonance imaging
(MRI) revealed active bilateral sacroiliitis (Fig.
1A). Echocardiography identified pulmonary
arterial hypertension, with a pulmonary arterial
pressure of less than 25 mmHg. Positive Raynaud’s
phenomenon using Raynaud’s scan and infrared
thermographic imaging was also confirmed.
AS was diagnosed according to the modified
New York criteria,
9 and MCTD was diagnosed by
the Alarcon-Segovia's criteria.
10 Polyarthritis
symptoms, except low back pain and Raynaud’s
phenomenon, improved with combination therapy
of hydroxychloroquine, NSAIDs, and low-dose
corticosteroids, and right shoulder pain resolved
following intraarticular steroid injection.
Four months later, the patient was readmitted
for buttock and sacroiliac joint pain. Clinically
significant pain reduction was not achieved using
computed tomography-guided intraarticular injec-
tion of 40 mg of triamcinolone acetate. A 25-mg
dose of soluble TNF- receptor, etanercept, was α
started twice weekly for four weeks in combi-
nation with NSAIDs and corticosteroids. The
patient had pain reduction and no occurrence of
lupus-like symptoms.
MRI examination of the sacroiliac joint was
assessed at 18 months. A significant decrease in
inflammation was identified, without development
of new lesions (Fig. 1B); this suggested the
effectiveness of etanercept for sacroiliitis in patients
with MCTD. Unfortunately, mild pulmonary
arterial hypertension of approximately 37 mmHg
developed. The patient’s treatment continued with
NSAIDs, hydroxychloroquine, low-dose cortico-
steroid, and a calcium channel blocker. She
reported a tolerable level of low back pain around
the sacroiliac joints.
DISCUSSION
MCTD patients share a number of clinical
features, including Raynaud’s phenomenon, puffy
hands, arthralgia, mild arthritis, myositis, and a
high level of antibodies to U1-RNP. Several
diagnostic criteria for MCTD have been described
in patients with overlapping manifestations of
SLE, RA, systemic sclerosis, and polymyositis.
2 In
addition, evidence of coexistence of spondyloar-
thropathy and connective tissue diseases, especially
Sj gren's syndrome or sicca syndrome, has pre ӧ -
viously been described.
11,12 Our case was a rare
concurrence of AS and MCTD.
Inflammatory manifestations in MCTD (including
arthritis, serositis, fever, and skin rash) respond
relatively well to NSAIDs or corticosteroids,
whereas patients with major organ involvement
tend to have persistent symptoms and often fail
to have significant improvement of Raynaud’s
phenomenon, interstitial lung disease, scleroderma-
Fig. 1. (A) Magnetic resonance coronal
fat suppressed T2-weighted image
(WI) of both sacroiliac joints showing
increased signal intensity within the
joint spaces and subchondral marrow
edema. Also present are subchondral
erosions and localized fat deposition
in the subchondral marrow spaces. (B)
After 18 months, significant improve-
ment of joint spaces with high signal
intensity on fat-suppressed T2-WI with
subchondral marrow edema identified
at the same level.
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like skin thickening, or pulmonary hypertension.
13
Arthritis in MCTD patients is responsive to
NSAIDs, hydroxychloroquine, and/ or low-dose
corticosteroids. Our patient with mild and
nonerosive polyarthritis had significant improve-
ment following combination therapy. Patients
with more destructive and erosive arthritis may
require more aggressive therapies, including
methotrexate, leflunomide, or azathioprine.
13
Data on TNF- blockers efficacy and safety have α
been recognized for multiple diseases with
inflammatory peripheral arthritis or axial arthritis
/spondylitis, including RA and AS.
7,8,14 Treatment
has been associated with diverse autoimmune
toxicities, including anti-double-stranded DNA
antibody induction and development of systemic,
lupus-like syndromes or a cutaneous, lupus-like
rash, although the etiology of aberrant immune
responses it is not clearly understood.
15 We
proposed that our patient with MCTD and
bilateral refractory sacroiliitis unresponsive to
NSAIDs and intraarticular steroid injections may
do well with TNF- blocker therapy, as do AS α
patients. However, two reports previously
described development of a lupus-like syndrome
in MCTD patients.
5,6 In this case we used etanercept
with good result, and without occurrence of
clinical features consistent with lupus-like
syndrome, such as myalgia, fever, arthralgia, or
skin rash.
As our patient had MRI scanning at 18 months,
it is impossible to predict time of sacroiliac lesion
improvement. However, a German study group
found significant regression on MRI of active
sacroiliitis following 6 weeks of treatment.
16 For
more accurate assessment, periodic MRI ex-
amination, development of an MRI scoring
system, and standardized dosing and duration of
etanercept in a large population study would be
required.
We report safe and effective use of etanercept
for sacroiliitis in a patient with MCTD with
evidence of symptomatic and radiological im-
provement. The results of these few case reports
show that there may be efficacy in the use of
anti-TNF therapy in MCTD-related polyarthritis. If
used, patients should be warned of the risk of
development of a lupus-like syndrome.
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